{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:08:20Z","timestamp":1790726900639,"version":"4.1.0"},"reference-count":174,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R00CA204601"],"award-info":[{"award-number":["R00CA204601"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Breast cancer pathogenesis, treatment, and patient outcomes are shaped by tumor-intrinsic genomic alterations that divide breast tumors into molecular subtypes. These molecular subtypes often dictate viable therapeutic interventions and, ultimately, patient outcomes. However, heterogeneity in therapeutic response may be a result of underlying epigenetic features that may further stratify breast cancer patient outcomes. In this review, we examine non-genetic mechanisms that drive functional changes to chromatin in breast cancer to contribute to cell and tumor fitness and highlight how epigenetic activity may inform the therapeutic response. We conclude by providing perspectives on the future of therapeutic targeting of epigenetic enzymes, an approach that holds untapped potential to improve breast cancer patient outcomes.<\/jats:p>","DOI":"10.3390\/cancers15154005","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T06:38:48Z","timestamp":1691390328000},"page":"4005","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Emerging Role of Epigenetic Modifiers in Breast Cancer Pathogenesis and Therapeutic Response"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-715X","authenticated-orcid":false,"given":"Richard Sean","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA"},{"name":"Department of Biology, Emory College, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5012-076X","authenticated-orcid":false,"given":"Kirti","family":"Sad","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorelle V.","family":"Fawwal","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA"},{"name":"Biochemistry, Cell & Developmental Biology Graduate Program, Emory University School of Medicine, Atlanta, GA 30311, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0181-3244","authenticated-orcid":false,"given":"Jennifer Marie","family":"Spangle","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e2013226","DOI":"10.1001\/jamanetworkopen.2020.13226","article-title":"Incidence Trends of Breast Cancer Molecular Subtypes by Age and Race\/Ethnicity in the US From 2010 to 2016","volume":"3","author":"Acheampong","year":"2020","journal-title":"JAMA Netw. Open."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"412","DOI":"10.5306\/wjco.v5.i3.412","article-title":"Biological subtypes of breast cancer: Prognostic and therapeutic implications","volume":"5","author":"Yersal","year":"2014","journal-title":"World J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Mayrovitz, H.N. (2022). Breast Cancer, Exon Publications.","DOI":"10.36255\/exon-publications-breast-cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"65024","DOI":"10.18632\/oncotarget.11344","article-title":"Luminal B breast cancer: Patterns of recurrence and clinical outcome","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4048\/jbc.2015.18.2.149","article-title":"Differences in Clinical Outcomes between Luminal A and B Type Breast Cancers according to the St. Gallen Consensus 2013","volume":"18","author":"Ahn","year":"2015","journal-title":"J. Breast Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Patel, A., Unni, N., and Peng, Y. (2020). The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer. Cancers, 12.","DOI":"10.3390\/cancers12082081"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer","volume":"380","author":"Huang","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-018-0850-9","article-title":"Therapeutic landscape in mutational triple negative breast cancer","volume":"17","author":"Shi","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature17676","article-title":"Landscape of somatic mutations in 560 breast cancer whole-genome sequences","volume":"534","author":"Davies","year":"2016","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/sj.onc.1201984","article-title":"Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer","volume":"17","author":"FitzGerald","year":"1998","journal-title":"Oncogene"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1053\/gast.2001.29611","article-title":"Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families","volume":"121","author":"Pharoah","year":"2001","journal-title":"Gastroenterology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.cell.2015.09.033","article-title":"Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer","volume":"163","author":"Ciriello","year":"2015","journal-title":"Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/hdy.2010.54","article-title":"Epigenetics and gene expression","volume":"105","author":"Gibney","year":"2010","journal-title":"Heredity"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrm.2017.94","article-title":"Emerging roles of linker histones in regulating chromatin structure and function","volume":"19","author":"Fyodorov","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_18","unstructured":"Simpson, B., Tupper, C., and Al Aboud, N.M. (2023). Genetics, DNA Packaging, StatPearls."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/38444","article-title":"Crystal structure of the nucleosome core particle at 2.8 A resolution","volume":"389","author":"Luger","year":"1997","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1093\/nar\/gkl338","article-title":"The tale beyond the tail: Histone core domain modifications and the regulation of chromatin structure","volume":"34","author":"Mersfelder","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2018.08.021","article-title":"Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy","volume":"837","author":"Biswas","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12038-020-00099-2","article-title":"Evaluation of post-translational modifications in histone proteins: A review on histone modification defects in developmental and neurological disorders","volume":"45","author":"Ramazi","year":"2020","journal-title":"J. Biosci."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Cavalieri, V. (2021). The Expanding Constellation of Histone Post-Translational Modifications in the Epigenetic Landscape. Genes, 12.","DOI":"10.3390\/genes12101596"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41576-022-00468-7","article-title":"Histone post-translational modifications\u2014Cause and consequence of genome function","volume":"23","author":"Burton","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/19491034.2016.1211217","article-title":"Chromatin remodelers: We are the drivers!!","volume":"7","author":"Tyagi","year":"2016","journal-title":"Nucleus"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"736935","DOI":"10.3389\/fcell.2021.736935","article-title":"Targeting Histone Modifications in Breast Cancer: A Precise Weapon on the Way","volume":"9","author":"Li","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Ennour-Idrissi, K., Dragic, D., Durocher, F., and Diorio, C. (2020). Epigenome-wide DNA methylation and risk of breast cancer: A systematic review. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07543-4"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5278","DOI":"10.3892\/ijo.2021.5278","article-title":"DNA methylation and breast cancer: A way forward (Review)","volume":"59","author":"Vietri","year":"2021","journal-title":"Int. J. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.semcancer.2020.08.009","article-title":"Epigenetic and breast cancer therapy: Promising diagnostic and therapeutic applications","volume":"83","author":"Sher","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"bqab088","DOI":"10.1210\/endocr\/bqab088","article-title":"Control of Breast Cancer Pathogenesis by Histone Methylation and the Hairless Histone Demethylase","volume":"162","author":"Trager","year":"2021","journal-title":"Endocrinology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41576-020-0278-0","article-title":"COMPASS and SWI\/SNF complexes in development and disease","volume":"22","author":"Cenik","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1126\/science.aah6893","article-title":"PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D","volume":"355","author":"Toska","year":"2017","journal-title":"Science"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.celrep.2019.02.111","article-title":"PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression","volume":"27","author":"Toska","year":"2019","journal-title":"Cell Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1016\/j.celrep.2016.05.046","article-title":"PI3K\/AKT Signaling Regulates H3K4 Methylation in Breast Cancer","volume":"15","author":"Spangle","year":"2016","journal-title":"Cell Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1158\/2767-9764.CRC-22-0158","article-title":"Targeting MLL Methyltransferases Enhances the Antitumor Effects of PI3K Inhibition in Hormone Receptor-positive Breast Cancer","volume":"2","author":"Jones","year":"2022","journal-title":"Cancer Res. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.tig.2020.07.011","article-title":"Mammalian SWI\/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies","volume":"36","author":"Centore","year":"2020","journal-title":"Trends Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","article-title":"The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers","volume":"34","author":"Razavi","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41588-019-0541-5","article-title":"ARID1A influences HDAC1\/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response","volume":"52","author":"Nagarajan","year":"2020","journal-title":"Nat. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41588-019-0554-0","article-title":"ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer","volume":"52","author":"Xu","year":"2020","journal-title":"Nat. Genet."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Sobczak, M., Pietrzak, J., Ploszaj, T., and Robaszkiewicz, A. (2020). BRG1 Activates Proliferation and Transcription of Cell Cycle-Dependent Genes in Breast Cancer Cells. Cancers, 12.","DOI":"10.3390\/cancers12020349"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41523-021-00248-2","article-title":"SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2","volume":"7","author":"Mehta","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.21873\/anticanres.11051","article-title":"Increased Brahma-related Gene 1 Expression Predicts Distant Metastasis and Shorter Survival in Patients with Invasive Ductal Carcinoma of the Breast","volume":"36","author":"Do","year":"2016","journal-title":"Anticancer. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.cell.2009.06.049","article-title":"Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes","volume":"138","author":"Wang","year":"2009","journal-title":"Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1128\/MCB.21.17.5979-5991.2001","article-title":"Regulation of transcription factor YY1 by acetylation and deacetylation","volume":"21","author":"Yao","year":"2001","journal-title":"Mol. Cell Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"11528","DOI":"10.1074\/jbc.M413930200","article-title":"Activation of Stat3 sequence-specific DNA binding and transcription by p300\/CREB-binding protein-mediated acetylation","volume":"280","author":"Wang","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1101\/gad.12.18.2831","article-title":"DNA damage activates p53 through a phosphorylation-acetylation cascade","volume":"12","author":"Sakaguchi","year":"1998","journal-title":"Genes. Dev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"a018762","DOI":"10.1101\/cshperspect.a018762","article-title":"Writers and readers of histone acetylation: Structure, mechanism, and inhibition","volume":"6","author":"Marmorstein","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41576-018-0072-4","article-title":"The many lives of KATs\u2014Detectors, integrators and modulators of the cellular environment","volume":"20","author":"Sheikh","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin modifications and their function","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.18632\/oncotarget.6922","article-title":"Histone H3 lysine 4 acetylation and methylation dynamics define breast cancer subtypes","volume":"7","author":"Messier","year":"2016","journal-title":"Oncotarget"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Guillemette, B., Drogaris, P., Lin, H.H., Armstrong, H., Hiragami-Hamada, K., Imhof, A., Bonneil, E., Thibault, P., Verreault, A., and Festenstein, R.J. (2011). H3 lysine 4 is acetylated at active gene promoters and is regulated by H3 lysine 4 methylation. PLoS Genet., 7.","DOI":"10.1371\/journal.pgen.1001354"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"14456","DOI":"10.1074\/jbc.M117.802074","article-title":"Acetylation on histone H3 lysine 9 mediates a switch from transcription initiation to elongation","volume":"292","author":"Gates","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Halasa, M., Wawruszak, A., Przybyszewska, A., Jaruga, A., Guz, M., Kalafut, J., Stepulak, A., and Cybulski, M. (2019). H3K18Ac as a Marker of Cancer Progression and Potential Target of Anti-Cancer Therapy. Cells, 8.","DOI":"10.3390\/cells8050485"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"14803","DOI":"10.1007\/s13277-016-5344-z","article-title":"Histone H3 lysine 23 acetylation is associated with oncogene TRIM24 expression and a poor prognosis in breast cancer","volume":"37","author":"Ma","year":"2016","journal-title":"Tumour Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1038\/s41467-021-22445-0","article-title":"Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling","volume":"12","author":"Huang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13148-019-0645-x","article-title":"The hyper-activation of transcriptional enhancers in breast cancer","volume":"11","author":"Li","year":"2019","journal-title":"Clin. Epigenetics"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.omtn.2022.08.029","article-title":"A novel oncogenic enhancer of estrogen receptor-positive breast cancer","volume":"29","author":"Bao","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1080\/15384101.2015.1106760","article-title":"Cell cycle-dependent changes in H3K56ac in human cells","volume":"14","author":"Stejskal","year":"2015","journal-title":"Cell Cycle"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.cell.2013.01.032","article-title":"Regulation of transcription through acetylation of H3K122 on the lateral surface of the histone octamer","volume":"152","author":"Tropberger","year":"2013","journal-title":"Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"109460","DOI":"10.1016\/j.celrep.2021.109460","article-title":"Metabolically controlled histone H4K5 acylation\/acetylation ratio drives BRD4 genomic distribution","volume":"36","author":"Gao","year":"2021","journal-title":"Cell Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/ng.154","article-title":"Combinatorial patterns of histone acetylations and methylations in the human genome","volume":"40","author":"Wang","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41392-019-0095-0","article-title":"Targeting epigenetic regulators for cancer therapy: Mechanisms and advances in clinical trials","volume":"4","author":"Cheng","year":"2019","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nature09692","article-title":"A unique chromatin signature uncovers early developmental enhancers in humans","volume":"470","author":"Bajpai","year":"2011","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1158\/0008-5472.CAN-08-3907","article-title":"Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome","volume":"69","author":"Elsheikh","year":"2009","journal-title":"Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.celrep.2013.09.009","article-title":"Chromatin modifications sequentially enhance ErbB2 expression in ErbB2-positive breast cancers","volume":"5","author":"Mungamuri","year":"2013","journal-title":"Cell Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.7150\/thno.51245","article-title":"H3K27 acetylation activated-COL6A1 promotes osteosarcoma lung metastasis by repressing STAT1 and activating pulmonary cancer-associated fibroblasts","volume":"11","author":"Zhang","year":"2021","journal-title":"Theranostics"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00432-020-03455-9","article-title":"A novel miRNA inhibits metastasis of prostate cancer via decreasing CREBBP-mediated histone acetylation","volume":"147","author":"Wang","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1038\/s41598-017-06790-z","article-title":"The Epigenetic Landscape of Promoter Genome-wide Analysis in Breast Cancer","volume":"7","author":"Dagdemir","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1038\/onc.2016.433","article-title":"Identification of MYST3 as a novel epigenetic activator of ERalpha frequently amplified in breast cancer","volume":"36","author":"Yu","year":"2017","journal-title":"Oncogene"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Roche, J. (2018). The Epithelial-to-Mesenchymal Transition in Cancer. Cancers, 10.","DOI":"10.3390\/cancers10020052"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nsmb.1432","article-title":"Nonprocessive methylation by Dot1 leads to functional redundancy of histone H3K79 methylation states","volume":"15","author":"Frederiks","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0092-8674(03)00114-4","article-title":"Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase","volume":"112","author":"Min","year":"2003","journal-title":"Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"7821","DOI":"10.1038\/ncomms8821","article-title":"DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression","volume":"6","author":"Cho","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_75","first-page":"3955","article-title":"Function of GCN5 in the TGF-beta1-induced epithelial-to-mesenchymal transition in breast cancer","volume":"16","author":"Zhao","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.molcel.2020.08.018","article-title":"PCAF-Mediated Histone Acetylation Promotes Replication Fork Degradation by MRE11 and EXO1 in BRCA-Deficient Cells","volume":"80","author":"Kim","year":"2020","journal-title":"Mol. Cell"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.18632\/oncotarget.2154","article-title":"Histone deacetylase inhibitor treatment induces \u2018BRCAness\u2019 and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells","volume":"5","author":"Ha","year":"2014","journal-title":"Oncotarget"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.biopha.2018.01.045","article-title":"Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells","volume":"99","author":"Marijon","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.molonc.2015.12.014","article-title":"Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma","volume":"10","author":"Rasmussen","year":"2016","journal-title":"Mol. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13046-018-0810-7","article-title":"PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1\/BRCA1 DNA damage repair complex in prostate cancer cells","volume":"37","author":"Yin","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/cdd.2015.173","article-title":"The acetyltransferase Tip60 contributes to mammary tumorigenesis by modulating DNA repair","volume":"23","author":"Bassi","year":"2016","journal-title":"Cell Death Differ."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.1038\/srep05372","article-title":"Rational design and validation of a Tip60 histone acetyltransferase inhibitor","volume":"4","author":"Gao","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1089\/omi.2019.0126","article-title":"TIP60 Inhibitor TH1834 Reduces Breast Cancer Progression in Xenografts in Mice","volume":"23","author":"Idrissou","year":"2019","journal-title":"OMICS"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.7314\/APJCP.2014.15.12.5001","article-title":"Garcinol, an acetyltransferase inhibitor, suppresses proliferation of breast cancer cell line MCF-7 promoted by 17beta-estradiol","volume":"15","author":"Ye","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.pmch.2014.11.002","article-title":"Recent advances in cancer therapeutics","volume":"54","author":"Chessum","year":"2015","journal-title":"Prog. Med. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.gene.2005.09.010","article-title":"Acetylation and deacetylation of non-histone proteins","volume":"363","author":"Glozak","year":"2005","journal-title":"Gene"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s12276-020-0382-4","article-title":"A short guide to histone deacetylases including recent progress on class II enzymes","volume":"52","author":"Park","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Luo, Y., and Li, H. (2020). Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs). Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228828"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"11262","DOI":"10.1038\/ncomms11262","article-title":"Insights into the activation mechanism of class I HDAC complexes by inositol phosphates","volume":"7","author":"Watson","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1111\/j.1582-4934.2011.01321.x","article-title":"Class IIa HDACs: From important roles in differentiation to possible implications in tumourigenesis","volume":"15","author":"Clocchiatti","year":"2011","journal-title":"J. Cell Mol. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"576946","DOI":"10.3389\/fcell.2020.576946","article-title":"The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy","volume":"8","author":"Li","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"110607","DOI":"10.1016\/j.biopha.2020.110607","article-title":"HDAC11: A rising star in epigenetics","volume":"131","author":"Liu","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"7751","DOI":"10.1073\/pnas.0903139106","article-title":"Genetic dissection of histone deacetylase requirement in tumor cells","volume":"106","author":"Haberland","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"13548","DOI":"10.1074\/jbc.M510023200","article-title":"Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer","volume":"281","author":"Wilson","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/sj.cdd.4401567","article-title":"Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1\/WAF1 expression, independent of histone deacetylase 1","volume":"12","author":"Huang","year":"2005","journal-title":"Cell Death Differ."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.4161\/cc.3.10.1195","article-title":"Specific and redundant functions of histone deacetylases in regulation of cell cycle and apoptosis","volume":"3","author":"Zhu","year":"2004","journal-title":"Cell Cycle"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1136\/jcp.2005.029165","article-title":"Expression of HDAC1 and CBP\/p300 in human colorectal carcinomas","volume":"60","author":"Ishihama","year":"2007","journal-title":"J. Clin. Pathol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/j.1349-7006.2001.tb02153.x","article-title":"Expression profile of histone deacetylase 1 in gastric cancer tissues","volume":"92","author":"Choi","year":"2001","journal-title":"Jpn. J. Cancer Res."},{"key":"ref_99","first-page":"1213","article-title":"HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer","volume":"7","author":"Shan","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10549-004-1668-2","article-title":"Histone deacetylase-1 and -3 protein expression in human breast cancer: A tissue microarray analysis","volume":"90","author":"Krusche","year":"2005","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Muller, B.M., Jana, L., Kasajima, A., Lehmann, A., Prinzler, J., Budczies, J., Winzer, K.J., Dietel, M., Weichert, W., and Denkert, C. (2013). Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-215"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"323","DOI":"10.4048\/jbc.2014.17.4.323","article-title":"Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast","volume":"17","author":"Seo","year":"2014","journal-title":"J. Breast Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"6962","DOI":"10.1158\/1078-0432.CCR-04-0455","article-title":"HDAC6 expression is correlated with better survival in breast cancer","volume":"10","author":"Zhang","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Garmpis, N., Damaskos, C., Dimitroulis, D., Kouraklis, G., Garmpi, A., Sarantis, P., Koustas, E., Patsouras, A., Psilopatis, I., and Antoniou, E.A. (2022). Clinical Significance of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer. J. Pers. Med., 12.","DOI":"10.3390\/jpm12101672"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.trsl.2014.05.003","article-title":"The nucleosome remodeling and deacetylase complex in development and disease","volume":"165","author":"Basta","year":"2015","journal-title":"Transl. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"5125","DOI":"10.1038\/s41467-019-12832-z","article-title":"ZEB1\/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancer","volume":"10","author":"Manshouri","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1038\/s41418-022-01010-2","article-title":"RUNX2 recruits the NuRD(MTA1)\/CRL4B complex to promote breast cancer progression and bone metastasis","volume":"29","author":"Yin","year":"2022","journal-title":"Cell Death Differ."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s13046-018-0988-8","article-title":"Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors","volume":"37","author":"Su","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/j.1442-2042.2007.01866.x","article-title":"Role of Wnt\/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1alpha","volume":"14","author":"Jiang","year":"2007","journal-title":"Int. J. Urol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"597743","DOI":"10.3389\/fonc.2020.597743","article-title":"Multifaceted WNT Signaling at the Crossroads between Epithelial-Mesenchymal Transition and Autophagy in Glioblastoma","volume":"10","author":"Coelho","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/labinvest.2011.201","article-title":"Wnt signaling induces epithelial-mesenchymal transition with proliferation in ARPE-19 cells upon loss of contact inhibition","volume":"92","author":"Chen","year":"2012","journal-title":"Lab. Investig."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13148-022-01228-4","article-title":"HDAC8 suppresses the epithelial phenotype and promotes EMT in chemotherapy-treated basal-like breast cancer","volume":"14","author":"Mieczkowska","year":"2022","journal-title":"Clin. Epigenetics"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10549-013-2784-7","article-title":"Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin","volume":"143","author":"Shah","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1128\/MCB.24.1.306-319.2004","article-title":"Snail mediates E-cadherin repression by the recruitment of the Sin3A\/histone deacetylase 1 (HDAC1)\/HDAC2 complex","volume":"24","author":"Peinado","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"11555","DOI":"10.1074\/jbc.M112.428920","article-title":"Keratin 8 and 18 loss in epithelial cancer cells increases collective cell migration and cisplatin sensitivity through claudin1 up-regulation","volume":"288","author":"Fortier","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1158\/0008-5472.CAN-19-1034","article-title":"MUC1-C Activates the NuRD Complex to Drive Dedifferentiation of Triple-Negative Breast Cancer Cells","volume":"79","author":"Hata","year":"2019","journal-title":"Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"522","DOI":"10.7150\/ijbs.4164","article-title":"TWIST represses estrogen receptor-alpha expression by recruiting the NuRD protein complex in breast cancer cells","volume":"8","author":"Fu","year":"2012","journal-title":"Int. J. Biol. Sci."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1093\/nar\/29.14.2905","article-title":"Estrogen receptor interaction with estrogen response elements","volume":"29","author":"Klinge","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/35050532","article-title":"Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor","volume":"3","author":"Mazumdar","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Heuer, J., Heuer, F., Sturmer, R., Harder, S., Schluter, H., Braga Emidio, N., Muttenthaler, M., Jechorek, D., Meyer, F., and Hoffmann, W. (2020). The Tumor Suppressor TFF1 Occurs in Different Forms and Interacts with Multiple Partners in the Human Gastric Mucus Barrier: Indications for Diverse Protective Functions. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072508"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"15050","DOI":"10.1074\/jbc.M311932200","article-title":"Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo","volume":"279","author":"Liu","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_122","first-page":"1","article-title":"Tamoxifen in early-stage estrogen receptor-positive breast cancer: Overview of clinical use and molecular biomarkers for patient selection","volume":"4","author":"Criscitiello","year":"2010","journal-title":"Onco Targets Ther."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"135","DOI":"10.6026\/97320630012135","article-title":"Molecular mechanisms and mode of tamoxifen resistance in breast cancer","volume":"12","author":"Ali","year":"2016","journal-title":"Bioinformation"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"E4482","DOI":"10.1073\/pnas.1620993114","article-title":"Embryonic transcription factor SOX9 drives breast cancer endocrine resistance","volume":"114","author":"Jeselsohn","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.1038\/s41388-021-01864-9","article-title":"SOX9 is a critical regulator of TSPAN8-mediated metastasis in pancreatic cancer","volume":"40","author":"Li","year":"2021","journal-title":"Oncogene"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1158\/1541-7786.MCR-19-0311","article-title":"SOX9 Is Essential for Triple-Negative Breast Cancer Cell Survival and Metastasis","volume":"18","author":"Ma","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/s41416-019-0625-0","article-title":"HDAC5-mediated deacetylation and nuclear localisation of SOX9 is critical for tamoxifen resistance in breast cancer","volume":"121","author":"Xue","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.semradonc.2015.05.003","article-title":"Radiotherapy in the Era of Precision Medicine","volume":"25","author":"Yard","year":"2015","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Ouellette, M.M., Zhou, S., and Yan, Y. (2022). Cell Signaling Pathways That Promote Radioresistance of Cancer Cells. Diagnostics, 12.","DOI":"10.3390\/diagnostics12030656"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/hep.29328","article-title":"Targeting histone deacetylase 4\/ubiquitin-conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells in mice","volume":"67","author":"Tsai","year":"2018","journal-title":"Hepatology"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Chiu, H.W., Yeh, Y.L., Wang, Y.C., Huang, W.J., Chen, Y.A., Chiou, Y.S., Ho, S.Y., Lin, P., and Wang, Y.J. (2013). Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0076340"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1158\/1535-7163.MCT-09-0038","article-title":"Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts","volume":"8","author":"Baschnagel","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.21037\/jgo-21-560","article-title":"Trichostatin A enhances radiosensitivity and radiation-induced DNA damage of esophageal cancer cells","volume":"12","author":"Wang","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13148-019-0800-4","article-title":"Elevated HDAC activity and altered histone phospho-acetylation confer acquired radio-resistant phenotype to breast cancer cells","volume":"12","author":"Sharda","year":"2020","journal-title":"Clin. Epigenetics"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Szczepanek, J., Skorupa, M., Jarkiewicz-Tretyn, J., Cybulski, C., and Tretyn, A. (2023). Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087235"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrd2227","article-title":"Vorinostat","volume":"6","author":"Grant","year":"2007","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1586\/era.10.88","article-title":"Romidepsin: A new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors","volume":"10","author":"Grant","year":"2010","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Braunstein, Z., Ruiz, M., Hanel, W., Shindiapina, P., Reneau, J.C., and Brammer, J.E. (2022). Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas. J. Pers. Med., 12.","DOI":"10.3390\/jpm12060964"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","article-title":"FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma","volume":"21","author":"Lee","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_140","first-page":"84","article-title":"Farydak (Panobinostat): First HDAC Inhibitor Approved for Patients with Relapsed Multiple Myeloma","volume":"9","author":"Raedler","year":"2016","journal-title":"Am. Health Drug. Benefits"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1158\/1535-7163.MCT-13-0345","article-title":"HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2","volume":"12","author":"Sabnis","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1200\/JCO.21.00944","article-title":"E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group","volume":"39","author":"Connolly","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S1470-2045(19)30164-0","article-title":"Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Jiang","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_144","unstructured":"Tollefsbol, T.O. (2016). Chapter 32\u2014Pharmacoepigenomics, Academic Press."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.18632\/oncotarget.13764","article-title":"Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines","volume":"8","author":"Feng","year":"2017","journal-title":"Oncotarget"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1515\/hsz-2020-0323","article-title":"Vorinostat exhibits anticancer effects in triple-negative breast cancer cells by preventing nitric oxide-driven histone deacetylation","volume":"402","author":"Palczewski","year":"2021","journal-title":"Biol. Chem."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2007-06-098061","article-title":"Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes","volume":"111","author":"Yang","year":"2008","journal-title":"Blood"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.3109\/10428194.2016.1160082","article-title":"Use of class I histone deacetylase inhibitor romidepsin in combination regimens","volume":"57","author":"Petrich","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41375-022-01780-1","article-title":"Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: Results of the PTCL13 phase Ib\/II study","volume":"37","author":"Chiappella","year":"2023","journal-title":"Leukemia"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/2040620715592567","article-title":"Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: A perspective review","volume":"6","author":"Sawas","year":"2015","journal-title":"Ther. Adv. Hematol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00280-019-03955-7","article-title":"Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: A California Cancer Consortium NCI\/CTEP sponsored trial","volume":"84","author":"Luu","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1186\/bcr3192","article-title":"Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat","volume":"14","author":"Tate","year":"2012","journal-title":"Breast Cancer Res."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/bjh.17080","article-title":"Phase II trial of single-agent panobinostat consolidation improves responses after sub-optimal transplant outcomes in multiple myeloma","volume":"193","author":"Mithraprabhu","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.breast.2018.12.001","article-title":"The role of histone deacetylase inhibitors in metastatic breast cancer","volume":"43","author":"Zucchetti","year":"2019","journal-title":"Breast"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1200\/JCO.2005.02.188","article-title":"Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma","volume":"23","author":"Ryan","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"614458","DOI":"10.3389\/fonc.2021.614458","article-title":"Chidamide Combined with Doxorubicin Induced p53-Driven Cell Cycle Arrest and Cell Apoptosis Reverse Multidrug Resistance of Breast Cancer","volume":"11","author":"Cao","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.breast.2022.10.018","article-title":"Clinical outcomes of tucidinostat-based therapy after prior CDK4\/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer","volume":"66","author":"Zhou","year":"2022","journal-title":"Breast"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3324\/haematol.2022.280996","article-title":"Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Phase IIb results","volume":"108","author":"Rai","year":"2023","journal-title":"Haematologica"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"10014","DOI":"10.1073\/pnas.180316197","article-title":"Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation","volume":"97","author":"Richon","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_162","first-page":"151","article-title":"Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: Defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines","volume":"2","author":"Glaser","year":"2003","journal-title":"Mol. Cancer Ther."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1038\/bcj.2015.83","article-title":"Romidepsin targets multiple survival signaling pathways in malignant T cells","volume":"5","author":"Valdez","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1111\/cas.12002","article-title":"Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase\/phosphatidylinositol 3-kinase dual inhibitors","volume":"103","author":"Saijo","year":"2012","journal-title":"Cancer Sci."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"30937","DOI":"10.1074\/jbc.M110.212035","article-title":"Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death","volume":"286","author":"Chowdhury","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/ijc.23243","article-title":"Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer","volume":"122","author":"Qian","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Sato, A., Asano, T., Isono, M., Ito, K., and Asano, T. (2014). Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells. BMC Urol., 14.","DOI":"10.1186\/1471-2490-14-71"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0092-8674(03)00939-5","article-title":"The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress","volume":"115","author":"Kawaguchi","year":"2003","journal-title":"Cell"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.18632\/oncotarget.27546","article-title":"Entinostat augments NK cell functions via epigenetic upregulation of IFIT1-STING-STAT4 pathway","volume":"11","author":"Idso","year":"2020","journal-title":"Oncotarget"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Truong, A.S., Zhou, M., Krishnan, B., Utsumi, T., Manocha, U., Stewart, K.G., Beck, W., Rose, T.L., Milowsky, M.I., and He, X. (2021). Entinostat induces antitumor immune responses through immune editing of tumor neoantigens. J. Clin. Investig., 131.","DOI":"10.1172\/JCI138560"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Zhang, P., Du, Y., Bai, H., Wang, Z., Duan, J., Wang, X., Zhong, J., Wan, R., Xu, J., and He, X. (2022). Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors. BMC Med., 20.","DOI":"10.1186\/s12916-022-02598-5"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12957-021-02157-x","article-title":"Clinicopathological factors affecting the effect of neoadjuvant chemotherapy in patients with gastric cancer","volume":"19","author":"Jiang","year":"2021","journal-title":"World J. Surg. Oncol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/1477-7819-12-280","article-title":"Comparison between better and poorly differentiated locally advanced gastric cancer in preoperative chemotherapy: A retrospective, comparative study at a single tertiary care institute","volume":"12","author":"Sun","year":"2014","journal-title":"World J. Surg. Oncol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"283ra251","DOI":"10.1126\/scitranslmed.aaa4442","article-title":"PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer","volume":"7","author":"Bosch","year":"2015","journal-title":"Sci. Transl. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/15\/4005\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:27:17Z","timestamp":1760128037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/15\/4005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":174,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["cancers15154005"],"URL":"https:\/\/doi.org\/10.3390\/cancers15154005","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,7]]}}}